Skip to main content
Eligibility
for people ages 6 years and up
Location
at Oakland, California and other locations
Dates
study started
estimated completion:

Description

Summary

This is an open-label extension study for patients who complete a Phase 3, placebo-controlled study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.

Official Title

A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Keywords

Cystic Fibrosis

Eligibility

You can join if…

Open to people ages 6 years and up

  • Completion of study treatment (placebo or active) in the previous Phase 3,double-blind study protocol (Protocol PTC124-GD-021-CF)

You CAN'T join if...

  • Ongoing participation in any other therapeutic clinical trial

Locations

  • Stanford University-Children's Hospital
    Palo Alto, California, 94304, United States
  • Children's Hospital Los Angeles
    Los Angeles, California, 90027, United States
  • Miller Children's Hospital Long Beach
    Long Beach, California, 90806, United States

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
PTC Therapeutics
ID
NCT02456103
Phase
Phase 3
Study Type
Interventional
Last Updated
May 2015